Summary The effects on experimental melanoma of a combination of recombinant human tumour necrosis factor alpha (rhTNFa) and carmustine (BCNU) were studied in vitro and in vivo. In vitro, BCNU alone was cytotoxic to murine B16 melanoma cells, and at all concentrations of BCNU this toxicity was increased by the addition of TNF. In vivo, BCNU and TNF, when given separately, caused tumour growth delay of B16 melanoma and of human melanoma xenografts in immune-deprived mice. The combination of TNF at low dose 2.5 x I0 U kg-' = 122 ng kg-') with BCNU (35 mg kg-') resulted in significant growth delay (compared with either drug alone) in B16 melanoma (P = 0.005). There was no significant increase in toxicity as assessed by weight loss and peripheral blood counts. Experiments with human melanoma xenografts yielded similar results (P = 0.001) but only at higher doses of TNF (1 x 106U kg-' = 489 ng kg-'). The enhancement of BCNU cytotoxicity by TNF may be important if it can be translated into patients with melanoma. A randomised study is now underway to investigate the clinical potential of this observation.
The treatment of patients with metastatic melanoma is disappointing. Chemotherapy with single drugs such as dacarbazine (Comis, 1976) and the nitrosoureas (Ahmann, 1976) achieves response rates of about 20%. Combination chemotherapy and high dose treatment can increase response rates but do not prolong survival (Lakhani et al., 1990) . Hence new strategies for the management of disseminated melanoma need to be devised.
Melanoma has, for some years, been considered a good candidate for treatment with biological agents. Intralesional therapy with Bacillus Calmette Guerin (BCG) caused regression of dermal disease (Rosenberg et al., 1982) but local therapy had little impact on the management of patients with disseminated disease. Systemic biological therapy using agents such as alpha interferon or interleukin 2 also achieved a response rate of up to 25% (Creagen et al., 1987; Rosenburg et al., 1987) .
Tumour necrosis factor (TNF) is a polypeptide originally identified in the serum of BCG treated mice which were subsequently exposed to endotoxin . The genes encoding both human and murine TNF have been expressed in E. coli. The human and murine proteins are 79% homologous (Marmenout et al., 1985) and show little species specificity in terms of biological effects. TNF alpha is produced by activated macrophages (Mannel et al., 1980) . A closely related protein, lymphotoxin or TNF beta is produced by activated lymphocytes and has 30% homology with TNF alpha (Pennica et al., 1984) and similar biological activity. TNF apha has been more extensively investigated as an anticancer agent than TNF beta. TNF is cytotoxic to many murine and human tumour cells, including some melanoma cell lines, in vitro (Helson et al., 1975; Fransen et al., 1975) .
In vivo, local administration of TNF has caused complete regression of some tumours (Haranaka et al., 1984) . Com- plete regression of syngeneic tumours and growth delay of human tumour xenografts in immune deprived mice have also been seen when TNF was used systemically (Haranaka et al., 1984; Balkwill et al., 1986; Brouckaert et al., 1986; Creasey et al., 1986) . This included some human melanomas grown as xenografts. The use of TNF as a single agent in patients with cancer is limited because of systemic toxicity (Selby et al., 1987) which occurs at doses which achieve serum levels below those associated with regression of experimental tumours in mice. The maximum tolerated intravenous dose in phase I studies was 9 x I05 U (440 pg) per m2 (Selby et al., 1987) . In vitro TNF increases the cytotoxicity of anthracyclines such as doxorubicin and podophyllotoxins such as etoposide (Alexander et al., 1987 (Marsh, 1986 After attachment the medium was removed from the dishes and replaced with Dulbecco's phosphate buffered saline 'A' (PBSA) containing BCNU at the concentrations indicated in the text. Cultures were incubated at 37°C for I h at which time this medium was removed from the dishes and replaced with 2 ml of fresh growth medium. To determine the effect of TNF on the toxicity of BCNU, 2,000 (I ng) units ml-' TNF was added to the growth medium after the removal of BCNU. Control cultures were treated with PBSA before changing to fresh growth medium. Cultures were incubated for 10-12 days at 37TC in an atmosphere of 5% C02, 10% 02 and 85% N2. At this time the medium was discarded from the dishes, the cells fixed in ethanol and stained with methylene blue. Colonies were counted using a colony counter (Anderson, UK). In vivo All animals in a single experiment were inoculated on the same day. Experiments were started when tumour diameters reached 0.3-0.5 cm. Tumours were measured with plastic calipers and volumes calculated by the formula (assuming spheroidal tumours): Drugs were injected intraperitoneally rather than intravenously as repeated injections were to be used. Control animals received carrier solution. BCNU, 35 mg kg-' was injected on day 0 and TNF was injected daily from day 0 for 5 days. Response was assessed by growth delay (Kopper & Steel, 1975) . The tumour volume at any time 't' (V,) was compared with the volume before treatment (V0). The ratio V,/V0 was calculated at each time point and the mean and standard error calculated for each treatment group. Mean V,/ V0 ( ± s.e.) for each group was plotted as a function of time to obtain growth curves. Tumour growth delay was expressed as the difference in time taken between untreated and treated groups of tumours to double in volume. In each group animals were killed when the tumour was greater than 1.5 cm or if there were signs of ulceration.
In some experiments animals were weighed concurrently with tumour measurements and the mean weight ( ± s.e.) of each group expressed as a ratio to the starting weight. Peripheral blood samples were taken from tail veins to assess haematological toxicity. Capillary samples of 20 ,il were taken into EDTA and the tail tip ligated and sterilised. Samples were counted on a Coulter S Plus and a multiplication factor (7.5-fold) used to determine actual WBC. Blood samples were performed on non-tumour bearing mice.
Results

In vitro
The effects of BCNU as a single agent and in combination with TNF on B16 cells in vitro are shown in Figure 1 . TNF alone had no effect on B 16 in vitro. BCNU reduced the The growth delays expressed as doubling times achieved with TNF and BCNU alone, and in combination for B16 melanoma are presented in Table II . A significant delay in doubling time was obtained with TNF alone (P = 0.001), BCNU alone (P = 0.001) and with the combination treatment (P = 0.001). However, the combination of TNF and BCNU was significantly better than either TNF alone (P = 0.001) or BCNU alone (P = 0.013). No cures were seen in any experiment and in all experiments tumour regrowth occurred. The effect of treatments on body weight is shown in Figure 2 . Control animals did not lose weight. Significant weight loss at day 3 was seen in the group receiving TNF alone (P = 0.05), and in the group receiving combination treatment (P = 0.005), although the increased weight loss in the combination group was not significantly greater than in the group receiving TNF alone. On day 10 weight loss in the group receiving TNF and BCNU was significantly greater than in the group receiving either TNF alone (P = 0.001) or BCNU alone (P = 0.025). All animals had regained their starting weight by the end of the experiment. The effect of treatments on peripheral white cell count (WBC) are shown in Figure 3 . BCNU as a single agent caused prolonged neutropenia with a nadir at day 7 and recovery to control values by day 30. TNF did not alter WBC. The addition of TNF to BCNU did not alter the nadir or pattern of recovery of WBC induced by BCNU. Immune deprived mice bearing human melanoma xenografts tolerated higher doses of TNF than C57 BL mice with B16 melanomas (Table I ) and a dose of I x 106 U (489 ng) per kg was used in xenograft experiments. The results of experiments on three different xenografts are shown in Table   II . The delay in doubling time was not significant with TNF alone (P = 0.057) but BCNU did cause significant growth delay (P = 0.029). There was significant growth delay with combination treatment (P = 0.014) and this was significantly longer than the delays seen with BCNU alone (P = 0.029). When the schedule of TNF was altered to 1 x 106 U (489 ng) per kg b.d. there was further enhancement of growth delay (Figure 4 ). In this experiment the dose of BCNU was constant. Figure 4a represents TNF once daily and Figure 4b shows the enhancement of growth delay with twice daily TNF. No toxicity was observed in these animals.
Discussion
These results have shown that the cytotoxic activity of BCNU on B16 melanoma cells in vitro was enhanced by the addition of TNF across a range of concentrations of BCNU. TNF in combination with BCNU increased the growth delay of the B16 melanoma compared with that seen using either BCNU or TNF alone.
The addition of TNF to BCNU did not result in increased toxicity as measured by the peripheral blood count. Although mice receiving combination treatment had weight loss of up to 20%, there were no toxic deaths, and all mice regained their starting weight by the end of the experiment. Enhanced growth delay in the absence of significant toxicity represents an improvement in the therapeutic index. Weight gain was concurrent with tumour regrowth and may suggest that factors involved in mediating tumour regression may also be involved mediating weight loss in these animals. TNF itself has been implicated as a mediator of cachexia (Cerami et al., 1985) but no significant weight loss was seen in the group receiving TNF alone compared with untreated control animals.
The enhanced antitumour effect with combination treatment was unlikely to be caused by altered BCNU pharmacokinetics as the addition of TNF did not affect the pattern of myelosuppression after BCNU. TNF may affect tumour vasculature (Nawroth & Stern, 1986) and hence drug permeability, but in these experiments BCNU was given with the initial dose of TNF making this explanation less likely. (Alexander et al., 1987; Das et al., 1989; Regenass et al., 1987 (Jones & Selby, 1990) .
Data from phase I trials suggest that the therapeutic index of TNF in man is small (Selby et al., 1987) 
